• 1
    Bryan CP. The Papyrus Ebers: Translated from the German Version. New York: D Appleton and Company; 1931.
  • 2
    Breasted JH. The Edwin Smith Surgical Papyrus: Hieroglyphic Transliteration, Translation and Commentary V1. Whitefish, MT: Kessinger Publishing; 2006.
  • 3
    Breasted JH. The Edwin Smith Papyrus: Some Preliminary Observations. Mémoire extrait du recueil d'études Égyptologiques. Paris: Librairie Ancienne Honoré Champion; 1922.
  • 4
    Papac RJ. Origins of cancer therapy. Yale J Biol Med 2002;74:391398.
  • 5
    Raven RW. The Theory and Practice of Oncology. Carnforth: The Parthenon Publishing Group; 1990.
  • 6
    Veiga P. Oncology and Infectious Diseases in Ancient Egypt: The Ebers Papyrus? Treatise on Tumours 857–877 and the Cases Found in Ancient Egyptian Human Material. Saarbrücken: VDM Verlag; 2009.
  • 7
    Sneader W. Drug Discoveries: A History. Chichester: John Wiley & Son Ltd.; 2005.
  • 8
    McGrew RE, McGrew MP. Encyclopedia of Medical History. London: Macmillan Press; 1985.
  • 9
    Magner LN. A History of Medicine, 2nd ed. Boca Raton, FL: Taylor and Francis Group; 1979.
  • 10
    Riddle JM. Ancient and medieval chemotherapy for cancer. Isis 1985;76:319330.
  • 11
    Gidding CEM, Kellie SJ, Kamps WA, De Graaf SSN. Vincristine revisited. Crit Rev Oncol/Hematol 1999;29:267287.
  • 12
    Chemical Heritage Foundation. Vinblastine: From Jamaica to cure. 2001. Available at: Accessed June 1, 2010.
  • 13
    Dunlop RH, Williams DM. Veterinary Medicine: An Illustrated History. St Louis, MO: Mosby; 1996.
  • 14
    DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res 2008;68:86438653.
  • 15
    Antman KH. Introduction: The history of arsenic trioxide in cancer therapy. Oncologist 2001;6 (Suppl 2):12.
  • 16
    Leu L, Mohassel L. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. Am J Health-Syst Pharm 2009;66:19131918.
  • 17
    National Institutes of Health. Bethesda, MD: Office of History. Available at: Accessed July 21, 2009.
  • 18
    Kisch B. Forgotten leaders in modern medicine. Valentin, Gruby, Remak, Auerbach. Trans Am Phil Soc 1954;44:139317.
  • 19
    Weiner DB. Raspail: Scientist, and Reformer. New York: Columbia University Press; 1968.
  • 20
    Virchow R. Cellular Pathology. London: John Churchill; 1860.
  • 21
    Reminick G. Nightmare in Bari: The World War II Liberty Ship Poison Gas Disaster and Cover-up. Palo Alto, CA: The Glencannon Press; 2001.
  • 22
    Krumbhaar EB, Krumbhaar HD. Blood and bone marrow in yellow cross gas (mustard gas) poisoning. J Med Res 1919;40:497506.
  • 23
    Clarke JH. The Cure of Tumours by Medicines with Especial Reference to the Cancer Nosodes. London: James Epps & Co. Ltd; 1908.
  • 24
    Furth J, Kahn MC. The transmission of leukemia of mice with a single cell. Am J Cancer 1937;31:276282.
  • 25
    Goodman LSA, Wintrobe MM, Dameshek W, et al. Nitrogen mustard therapy: Use of methyl-bis (β-chloroethyl) amine hydrochloride and tris (β-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia, and certain allied and miscellaneous disorders. J Am Med Assoc 1946;132:126132.
  • 26
    Chabner BA, Roberts TG Jr. Chemotherapy and the war on cancer. Nat Rev Cancer 2005;5:6572.
  • 27
    Southern G. Poisonous Inferno. Shrewsbury: Airlife Publishing Ltd.; 2002.
  • 28
    Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukemia in children produced by folic acid antagonists, 4-aminopteroyl-glutamic acid (aminopeterin). N Engl J Med 1948;238:787793.
  • 29
    National Library of Medicine (US). Profiles in Science. The Mary Lasker Papers. Bethesda, MD: National Library of Medicine; 2000. Available at: Accessed March 18, 2008.
  • 30
    Bishop JM. Mary Lasker and her prizes: An appreciation. J Am Med Assoc 2005;294:14181419.
  • 31
    Berg P. Reflections on the Lasker prize for basic biomedical research. J Am Med Assoc 2005;294:14191420.
  • 32
    Marshall BJ. The Lasker awards: Celebrating scientific discovery. J Am Med Assoc 2005;294:14201421.
  • 33
    Edwards RG. The Lasker Foundation and recognition of scientific excellence. J Am Med Assoc 2005;294:14221423.
  • 34
    Johnson IS, Armstrong JG, Gorman M, Burnett JP Jr. The vinca alkaloids: A new class of oncolytic agents. Cancer Res 1963;23:13901427.
  • 35
    DeVita VT. Principles of chemotherapy. In: DeVitaVT, HellmanS, RosenbergSA, eds. Cancer: Principles and Practice of Oncology, 4th ed. Philadelphia, PA: JB Lippincott; 1993:276202.
  • 36
    Simpson-Herren L, Wheeler GP. Howard Earle Skipper: In memoriam. Cancer Res 2006;66:1203512036.
  • 37
    Skipper HE, Schabel FR Jr, Wilcox WS. Experimental evaluation of potential anticancer agents: XIII. On the criteria and kinetics associated with “curability” of experimental leukemia. Cancer Chemother Rep 1964;35:1111.
  • 38
    Norton L, Simon R, Brereton HD, Bogden AE. Predicting the course of Gompertzian growth. Nature 1976;264:542545.
  • 39
    Olshansky SJ, Carnes BA. Ever since Gompertz. Demography 1997;34:115.
  • 40
    Dembo A. Spontaneous mutations to chemotherapy resistance: Implications of the Goldie-Coldman model for the management of ovarian cancer. J Clin Oncol 1984;2:13111316.
  • 41
    Day RS. Treatment sequencing, asymmetry and uncertainty: Protocol strategies for combination chemotherapy. Cancer Res 1986;46:38763885.
  • 42
    Hunter T. Treatment for chronic myelogenous leukemia: The long road to imatinib. J Clin Invest 2007;117:20362043.
  • 43
    Jeglum KA. The history and future of canine lymphoma monoclonal antibody 231. Cancer Therapy 2009;7:5962.
  • 44
    Innes JRM, Parry HB, Berger J. Leukaemia in dogs including a record of a case treated by urethane. Vet J 1946;102:383393.
  • 45
    Holland JR, Hosley H, Scharlau C, et al. A controlled trial of urethane treatment in multiple myeloma. Blood 1966;27:32842.
  • 46
    Hara K, Harris RA. The anesthetic mechanism of urethane: The effects on neurotransmitter-gated ion channels. Anesth Analg 2002;94:313318.
  • 47
    Bloom F. Effect of cortisone on mast cell tumors (mastocytoma) of the dog. Proc Nat Soc Exptl Biol Med 1952;4:651654.
  • 48
    Cortisone for mast cell tumors of dogs. J Am Vet Med Assoc 1953;102:378.
  • 49
    Pasero G, Marson P. Wars in the history or rheumatology. Reumatismo 2007;59:332337.
  • 50
    The new president of the Society of Pharmacological and Environmental Pathologists. Toxicol Pathol 1977;5:34.
  • 51
    McCoy JR, Allison JB, Crossley ML, Wannemacher RW. Chemothearpy of canine cancer with N-(3-oxapentamethylene)-N′,N″-diethylenephosphoramide (MEPA). Am J Vet Res 1956;17:9097.
  • 52
    Irfan M. Studies on the peripheral blood picture of the dog and cat in health and disease: Part II lymphatic leukosis in dogs. Irish Vet J 1958;15:8611.
  • 53
    McCoy JR. Trial of chemotherapeutic agents on spontaneous tumors in dogs. Ann New York Acad Sci 1958:850854.
  • 54
    Meier H. Some aspects of experimental and spontaneous tumorigenesis in animals. Adv Vet Sci 1962;7:4385.
  • 55
    McClelland RB. Cyclophosphamide therapy in lymphoma of the dog. Cornell Vet 1963;53:319322.
  • 56
    Moldovanu G, Friedman M, Miller DG. Treatment of canine malignant lymphoma with surgery and chemotherapy. J Am Vet Med Assoc 1966;148:153165.
  • 57
    Old LY, Boyse EA, Campbell HA, et al. Treatment of lymphosarcoma in the dog with l-asparaginase. Cancer 1967;20:10661070.
  • 58
    Brick JO, Roenigk WJ, Wilson GP. Chemotherapy of malignant lymphoma in dogs and cats. J Am Vet Med Assoc 1968;153:4752.
  • 59
    Madewell BR. Chemotherapy for canine lymphosarcoma. J Am Vet Res 1975;36:15251528.
  • 60
    Smith DM, Kirk GR. Some systemic effects of adriamycin on the dog. J Am Anim Hosp Assoc 1976;12:9297.
  • 61
    Henness AM, Theilen GH, Park RD, Buhles WC. Combination therapy for canine osteosarcoma. J Am Vet Med Assoc 1977;170:10761081.
  • 62
    Schoster JV, Wyman M. Remission of orbital sarcoma in a dog using doxorubicin therapy. J Am Vet Med Assoc 1978;172:11011103.
  • 63
    Calvert CA, Leifer CE. Doxorubicin for treatment of canine lymphosarcoma after development of resistance to combination chemotherapy. J Am Vet Med Asoc 1981;179:10111012.
  • 64
    Crow SE, Theilen GH, Benjamini E, et al. Chemoimmunotherapy for canine lymphosarcoma. Cancer 1977;40:21022108.
  • 65
    Weiden PL, Storb R, Deeg RH, et al. Prolonged disease-free survival in dogs with lymphoma after total-body irradiation and autologous marrow transplantation consolidation of combination-chemotherapy induced remissions. Blood 1979;54:10391049.
  • 66
    Pinkel D. The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 1958;18:853856.
  • 67
    Price SL, Frazier D. Use of body surface area (BSA)-based dosages to calculate chemotherapeutic drug dose in dogs: I. Potential problems with current BSA formulae. J Vet Intern Med 1998;12:267271.
  • 68
    Ogilvie GK, Cockburn CA, Tranquilli WJ, et al. Hypotension and cutaneous reactions associated with intravenous administration of etoposide in the dog. Am J Vet Res 1988;49:13671370.
  • 69
    Hohenhaus AE, Matus RE. Etoposide (VP-16): Retrospective analysis of treatment in 13 dogs with lymphoma. J Vet Intern Med 1990;4:239241.
  • 70
    Thomas ED. Bone marrow transplantation—past, present, future. Nobel Lecture 1990. Available at: Accessed June 1, 2010.
  • 71
    National Veterinary Laboratories Inc. Franklin Lakes. About us—who we are. 2010. Available at: Accessed June 1, 2010.
  • 72
    Nagournay E. New York Times 2001. Available at: Accessed June 1, 2010.
  • 73
    Bergman PJ, Camps-Palau MA, McKnight JA, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006;24(21):45824585.
  • 74
    Moya del Pino B. Of dogs and men: Lessons on the fight against cancer. NCI Cancer Bull 2006;3:35.